<DOC>
	<DOCNO>NCT02713620</DOCNO>
	<brief_summary>This follow study publish article entitle `` Comparison immunogenicity safety four dose four double dos vs. standard dos hepatitis B vaccination HIV-infected adult : randomize , control trial '' Chaiklang K , Wipasa J , Chaiwarith R , Praparattanapan J , Supparatpinyo K. publish PLoS One . 2013 Nov 12 ; 8 ( 11 ) : e80409 . doi : 10.1371/journal.pone.0080409 . eCollection 2013 . ClinicalTrials.gov ; NCT1289106 . This study aim evaluate efficacy HBV vaccination regimens use either four standard dose four double dos compare current standard regimen three dos HIV-infected adult northern Thailand . In addition , investigator evaluate efficacy HBV vaccination current standard regimen three dos healthy adult HIV-infected patient .</brief_summary>
	<brief_title>Hepatitis B Vaccination HIV-infected Adults</brief_title>
	<detailed_description>From February 4 , 2011 May 4 , 2012 , 132 HIV-infected adult CD4+ cell count &gt; 200 cells/mm3 , undetectable plasma HIV-1 RNA , negative HBV marker randomly assign receive one three recombinant vaccine ( Hepavax-Gene® Berna , Korea ) regimens : 20 μg IM month 0 , 1 , 6 ( Standard dose group , n=44 ) , 20 μg IM month 0 , 1 , 2 , 6 ( four dos group , n=44 ) , 40 μg IM month 0 , 1 , 2 , 6 ( four double dos group , n=44 ) . There another group healthy individual receive standard dose 20 μg IM month 0 , 1 , 6 recruit time protocol . In brief , month 7 12 , percentages responder ( anti-HBs ≥10 mIU/mL ) 88.6 % 70.4 % Standard dose group , 93.2 % 86.4 % four dos group , ( P=0.713 0.119 ) , 95.4 % 88.6 % four double dos group , ( P=0.434 0.062 ) , respectively . This current study aim evaluate efficacy different HBV vaccination regimens 36 month vaccination . In addition compare group use four standard dose four double dos current standard regimen three dos HIV-infected adult northern Thailand , investigator also compare efficacy current standard regimen 3 dos HIV-infected healthy individual .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy Group 1.1 ≥18 year old , 1.2 negative hepatitis B surface antigen ( HBsAg ) , antibody hepatitis B surface antigen ( antiHBs ) , antibody hepatitis B core antigen ( antiHBc ) , history previous vaccine 1.3 negative antibody hepatitis C virus ( antiHCV ) 1.4 receive three intramuscular injection 20 μg recombinant HBV vaccine ( HepavaxGene® Berna , Korea ) month 0 , 1 , 6 February 4 , 2011 May 4 , 2012 , time study ClinicalTrials.gov ; NCT1289106 . conduct . 1.4 willing sign inform consent 2 . HIV Group 1 2.1 HIV1 infection 2.2 ≥18 year old , 2.3 CD4+ cell count &gt; 200 cells/mm3 , 2.4 undetectable plasma HIV1 RNA , 2.5 negative hepatitis B surface antigen ( HBsAg ) , antibody hepatitis B surface antigen ( antiHBs ) , antibody hepatitis B core antigen ( antiHBc ) , history previous vaccine , 2.6 negative antibody hepatitis C virus ( antiHCV ) , 2.7 active opportunistic infection ( time screen ) , 2.8 participate ClinicalTrials.gov ; NCT1289106.and receive three intramuscular injection 20 μg recombinant HBV vaccine ( HepavaxGene® Berna , Korea ) month 0 , 1 , 6 2.9 willing sign inform consent 3 . HIVGroup 2 3.1 HIV1 infection 3.2 ≥18 year old , 3.3 CD4+ cell count &gt; 200 cells/mm3 , 3.4 undetectable plasma HIV1 RNA , 3.5 negative hepatitis B surface antigen ( HBsAg ) , antibody hepatitis B surface antigen ( antiHBs ) , antibody hepatitis B core antigen ( antiHBc ) , history previous vaccine , 3.6 negative antibody hepatitis C virus ( antiHCV ) , 3.7 active opportunistic infection ( time screen ) , 3.8 participate ClinicalTrials.gov ; NCT1289106.and receive four intramuscular dos 20 μg vaccine month 0 , 1 , 2 , 6 3.9 willing sign inform consent 4 . HIV Group 3 4.1 HIV1 infection 4.2 ≥18 year old , 4.3 CD4+ cell count &gt; 200 cells/mm3 , 4.4 undetectable plasma HIV1 RNA , 4.5 negative hepatitis B surface antigen ( HBsAg ) , antibody hepatitis B surface antigen ( antiHBs ) , antibody hepatitis B core antigen ( antiHBc ) , history previous vaccine , 4.6 negative antibody hepatitis C virus ( antiHCV ) , 4.7 active opportunistic infection ( time screen ) , 4.8 participate ClinicalTrials.gov ; NCT1289106.and receive four intramuscular double dos ( 40 μg ) month 0 , 1 , 2 , 6 4.9 willing sign inform consent For HIV group 1 , 2 , 3 1. active malignancy receive chemotherapy radiation , 2. immunocompromised condition besides HIV ( e.g. , solid organ transplant ) , 3. receive immunosuppressive ( e.g. , corticosteroid ≥ 0•5 mg/kg/day ) immunomodulating treatment last six month screen visit , 4. renal insufficiency ( creatinine clearance &lt; 30 mL/min ) , 5. decompensated cirrhosis ( ChildPugh class C )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>HBV vaccination , immunity</keyword>
</DOC>